As oral drug delivery moves beyond the small intestine, ileocolonic targeting is emerging as a key enabler for next‑generation therapeutics. This article explores how colonic delivery technologies – including pH‑dependent polymers, multi‑trigger coatings and ready‑to‑fill […]

Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for […]

The global probiotics market has experienced sustained and rapid growth over the past decade, driven by increasing consumer awareness of gut health, immunity, and the central role of the microbiome in overall well‑being. Discussions at […]

Gut microbiome research has changed. Many studies no longer stop at identifying which microbes are present. They are now also looking at what those microbes are doing, often by measuring the metabolites they produce or […]

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial. […]

When the liver fails, toxins – such as ammonia – that should be filtered from the blood build up and reach the brain. The result is hepatic encephalopathy (HE), a devastating neurological complication of liver […]